ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
A multifaceted global approach to addressing antimicrobial resistance
Dr. Caroline Forkin, VP Clinical Research Services, considers the best approach to address antimicrobial resistance.
The future of clinical trials
Dr. Greg Licholai discusses key market trends, the future of clinical trials and the acquisition of PRA.
The waterfall effect of digital health technology on unifying healthcare and clinical research
Isaac R Rodriguez-Chavez contributes to the DPHARM Autumn 2021 newsletter, discussing the use of digital health to maximise efficiencies in decentralised clinical trials.
CROs: Yesterday, today, and tomorrow
ICON's Kent Thoelke discusses today’s key trends for CROs, including the increasing adoption of decentralised clinical trials (DCTs) and the growing use of remote monitoring to collect data.
The new oncology: What makes CGT cancer trials different
Brandon Fletcher, CGT Principal, discusses how oncology is adapting to cell and gene therapy, and what can be done to improve take-up across the industry.
Top 10 factors to design and deploy a decentralised clinical trial
Dr. Isaac Rodriguez-Chavez considers the top 10 factors when designing and deploying a decentralised clinical trial.
Europe’s emerging biotechs: Challenges, opportunities and funding
John Macdonald, Vice President, Venture & Financial Alliances, examines the European biotech sector – its expertise and opportunities, and potential for growth.
Recruiting patients for real-world studies
William Maier, VP Rare Diseases, Drug Development Sciences, considers the benefits of digital recruitment campaigns for recruiting patients for real-world studies.
Communicating for change - creating effective medical communications
Chris O'Toole, VP Commercial Solutions, discusses best practices for medical communications to improve interactions and results.
Recent advances and future challenges using biomarkers in oncology precision medicine
Dr. Brian Huber outlines the role biomarkers play in guiding therapeutic strategies.